Blueprint Medicines Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Blueprint Medicines (BPMC) Tops Q1 EPS by 14c, Revenues Beat
April 29, 2021 7:48 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($1.72), $0.14 better than the analyst estimate of ($1.86). Revenue for the quarter came in at $21.58 million versus the consensus estimate of $17.25 million.
"In recent months, we made significant progress toward achieving our key 2021 portfolio goals, illustrating our... More
